natgillin/translations-raw huggingface dataset:
After accounting for body weight differences, no clinically significant differences in the pharmacokinetic properties of canakinumab were observed between CAPS and SJIA patients.
Nakon što se uzmu u obzir razlike u tjelesnoj težini, nisu bile uočene značajne razlike u farmakokinetičkim svojstvima kanakinumaba između bolesnika s CAPS-om i onih sa SJIA-om.
After activation: Do not store above 30°C
Nakon aktivacije: Ne čuvati na temperaturi iznad 30°C.
After activation: use within 12 hours
Nakon aktivacije: upotrijebiti u roku od 12 sati
After adding the solvent, shake the vial moderately for a minimum of 30 seconds until a uniform suspension is formed.
Nakon što dodate otapalo, umjereno tresite bočicu najmanje 30 sekundi dok ne dobijete jednoličnu suspenziju.
After addition of either dextrose 50 mg/ml (5%) solution for injection, or water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection, the contents of the vial are mixed by swirling gently to facilitate reconstitution.
Nakon dodavanja otopine glukoze za injekciju u koncentraciji 50 mg/ml (5%), vode za injekciju ili otopine natrijevog klorida za injekciju u koncentraciji od 9 mg/ml (0,9%), sadržaj bočice se miješa laganom vrtnjom kako bi se olakšala rekonstitucija.
After adjusting for differences in creatinine clearance and body weight, elderly subjects had a 12.5% higher AUC than young subjects.The population pharmacokinetic analysis covering patients in the age range 16-
Nakon prilagodbe za razlike u klirensu kreatinina i tjelesnoj težini, stariji ispitanici imali su 12,5% višu AUC od mladih ispitanika.
After administering half of the dose in one nostril, administer the other half of the dose in the other nostril immediately or shortly thereafter.
Odmah ili ubrzo nakon primjene prve polovice doze u jednu nosnicu, primijeniti drugu polovicu doze u drugu nosnicu.
After administering the dose, the PegIntron pre-filled pen and any unused solution contained in it is to be disposed of in accordance with local requirements.
Nakon primjene doze lijeka, PegIntron napunjenu brizgalicu i neiskorištenu otopinu preostalu u njoj potrebno je zbrinuti sukladno lokalnim propisima.
After administering the dose, the ViraferonPeg pre-filled pen and any unused solution contained in it is to be disposed of in accordance with local requirements.
Nakon primjene doze lijeka, ViraferonPeg napunjenu brizgalicu i neiskorištenu otopinu preostalu u njoj potrebno je zbrinuti sukladno lokalnim propisima.
After administration at 0.15 mg/kg on a daily (n=6) or twice-weekly (n=3) regimen, an approximate 2-fold accumulation of AsIII was observed as compared to a single infusion.
Nakon primjene režima od 0,15 mg/kg dnevno (n=6) ili dvaput tjedno (n=3), približna dvostruka akumulacija AsIII primijećena je u usporedbi s pojedinačnom infuzijom.
After administration of 1,662, 500IU twice daily for 7 days in adult, adolescent and paediatric cystic fibrosis patients mean C max values of total colistimethate of up to 455ng/ml (adult mean) were observed.
Nakon primjene lijeka Colobreathe 1 662 500 IU dvaput na dan tijekom 7 dana u odraslih, adolescenata i djece s cističnom fibrozom, zabilježene su prosječne vrijednosti C max ukupnog kolistimetata do 455 ng/ml (prosjek u odraslih).
After administration of 14C-eribulin to patients, approximately 82% of the dose was eliminated in faeces and 9% in urine indicating that renal clearance is not a significant route of eribulin elimination.
Nakon davanja 14C-eribulina bolesnicima, otprilike 82% doze eliminiralo se stolicom, a 9% mokraćom, što pokazuje da bubrežni klirens nije značajan put eliminacije eribulina.
After administration of 14C-posaconazole as oral suspension, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose).
Nakon primjene 14C-posakonazola u obliku oralne suspenzije, radioaktivnost se uglavnom otkrila u stolici (77% radioaktivno označene doze), a glavnu je komponentu činio izvorni spoj (66% radioaktivno označene doze).
After administration of 30 mg/m2 doses, steady-state conditions are reached for tegafur, gimeracil, and oteracil at the latest by Day 8.
Nakon primjene doza od 30 mg/m2, postignuti su uvjeti stanja dinamičke ravnoteže za tegafur, gimeracil i oteracil najdulje do 8. dana.
After administration of a 50 mg [14C]-dapagliflozin dose, 96% was recovered, 75% in urine and 21% in feces.
Nakon primjene [14C]-dapagliflozina u dozi od 50 mg utvrđeno je 96% lijeka, od čega 75% u mokraći i 21% u fecesu.
After administration of a 75 mg radiolabelled dose to healthy volunteers, cinacalcet was rapidly and extensively metabolised by oxidation followed by conjugation.
Nakon administracije radioaktivno obilježene doze od 75 mg zdravim dobrovoljcima, sinakalcet se brzo i ekstenzivno metabolizira oksidacijom, a nakon toga konjugacijom.
After administration of a radiolabeled 14C-etravirine dose, 93.7% and 1.2% of the administered dose of 14C-etravirine could be retrieved in faeces and urine, respectively.
Nakon primjene doze radioaktivno obilježenog C14-etravirina u stolici je nađeno 93,7%, a u mokraći 1,2% primijenjene doze etravirina C14.
After administration of a radiolabelled dose of leflunomide, radioactivity was equally excreted in faeces, probably by biliary elimination, and in urine.
Nakon primjene radioaktivno obilježenog leflunomida radioaktivnost se jednako pojavila u stolici, vjerojatno eliminacijom putem žuči, i u mokraći.
After administration of a two-fold overdose a rectal temperature increase of up 2.1ºC may occur 1 day after the injection and then rectal temperatures return to normal values.
1 dan nakon primjene dvostruke doze može doći do prolaznog povišenja rektalne temperature do 2,1°C koja se nakon toga vraća u normalu.
After administration of a two-fold overdose, a rectal temperature increase of up 2.1 ºC may occur 1 day after the injection and then rectal temperatures return to normal values.
Nakon primjene dvostruke doze može doći do povišenja rektalne temperature od 2,1 °C, prvi dan nakon cijepljenja, a zatim se rektalna temperatura vraća na normalne vrijednosti.
After administration of Amyvid, you should:
Nakon primjene lijeka Amyvid morate:
After administration of any asparaginase preparation, close monitoring of bilirubin, hepatic transaminases, blood/urinary glucose, coagulation parameters (e.g.
Nakon primjene bilo kojeg pripravka asparaginaze preporučuje se pomno praćenje bilirubina, jetrenih transaminaza, glukoze u krvi/mokraći, parametara koagulacije (npr.
After administration of enoxaparin sodium, the injection site should not be rubbed.
Nakon primjene enoksaparinnatrija mjesto injekcije ne smije se trljati.
After administration of enoxaparin sodium, the injection site should not be rubbed.
Nakon primjene enoksaparinnatrija mjesto injiciranja ne smije se trljati.
After administration of epoetin beta, the number of erythrocytes, the Hb values and reticulocyte counts increase as well as the 59Fe-incorporation rate.
Nakon primjene epoetina beta raste broj eritrocita, vrijednost hemoglobina, broj retikulocita te brzina ugradnje željeza 59Fe.
After administration of erythropoietin, the number of erythrocytes, the Hb values and reticulocyte counts increase as well as the 59Fe-incorporation rate.
Nakon primjene eritropoetina, dolazi do porasta broja eritrocita, vrijednosti hemoglobina, porasta broja retikulocita kao i porasta brzine ugradnje željeza59.
After administration of multiple dose of 400 mg or 300 mg of Abilify Maintena, the mean aripiprazole terminal elimination half-life is respectively 46.5 and 29.9 days presumably due to absorption rate- limited kinetics.
Nakon primjene višestruke doze od 400 mg ili 300 mg lijeka Abilify Maintena, srednja vrijednost terminalnog poluvijeka eliminacije aripiprazola je 46,5 dana odnosno 29,9-dana, pretpostavlja se zbog kinetike ograničene brzinom apsorpcije.
After administration of NUEDEXTA 23 mg/9 mg to 14 extensive metabolizers, the elimination half- life of dextromethorphan was 18.8 hours and the elimination half-life of quinidine was 9.6 hours.
Nakon primjene lijeka NUEDEXTA 23 mg/9 mg u 14 ekstenzivnih metabolizatora, poluživot eliminacije dekstrometorfana bio je 18,8 sati a poluživot eliminacije kinidina 9,6 sati.
After administration of Praxbind, other antithrombotic therapy (e.g. low-molecular weight heparin) can be started at any time, if the patient is clinically stable and adequate haemostasis has been achieved.
Nakon primjene Praxbinda, u svakom trenutku se može započeti s drugom antitrombotskom terapijom (npr. heparinom niske molekulske mase), ako je bolesnik klinički stabilan te je postignuta odgovarajuća hemostaza.
After administration of rFVIIa, prothrombin time (PT) and activated partial thromboplastin time (aPTT) have been shown to shorten, however no correlation has been demonstrated between PT and aPTT and clinical efficacy of rFVIIa.
Nakon primjene rFVIIa, protrombinsko vrijeme (PV) i aktivirano parcijalno tromboplastinsko vrijeme (aPTV) skraćuju se, ali nema dokazane korelacije između PV i aPTV te kliničke djelotvornosti rFVIIa.
After administration of Scintimun
Nakon primjene Scintimuna
After administration of the drug, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Nakon primjene , zatvorite bočicu čepom, isperite mjernu štrcaljku toplom vodom i pustite da se osuši.
After administration of the medicine radiolabelled with Cuprymina has been performed
Nakon primjene lijeka radioobilježenog Cupryminom
After administration of the medicine radiolabelled with EndolucinBeta, you should
Nakon primjene lijeka koji je radioaktivno označen EndolucinBetom, morate
After administration of the medicine radiolabelled with Lumark has been performed
Nakon primjene lijeka koji je radioaktivno označen Lumarkom
After administration of the nivolumab dose, flush the line with sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) glucose solution for injection.
Nakon primjene doze nivolumaba isperite liniju otopinom natrijeva klorida za injekciju od 9 mg/ml (0,9%) ili otopinom glukoze za injekciju od 50 mg/ml (5%).
After administration of the recommended dose lung concentrations of 0.060–0.066 µg/ml were found at 2 and 12 hours post-treatment.
Uz preporučenu dozu, koncentracije izmjerene u plućima 2 sata i 12 sati nakon primjene iznosile su od 0,060 do 0,066 µg/ml.
After administration of the required volume from the 5 ml syringe with the dissolved suspension of raltegravir, the remaining suspended medicine cannot be re-used and should be discarded (see section 6.6).
Nakon primjene željenog volumena štrcaljkom od 5 ml koja sadrži otopljenu suspenziju raltegravira, preostali suspendirani lijek ne može se ponovno upotrijebiti te ga treba zbrinuti (vidjeti dio 6.6).
After administration of the veterinary medicinal product close the bottle tightly with the cap, wash the measuring syringe with water and let it dry.
Poslije primjene veterinarsko-medicinskog proizvoda bocu čvrsto zatvorite zatvaračem, mjernu štrcaljku operite s vodom i pustite da se osuši.
After administration of the veterinary medicinal product close the bottle tightly with the cap, wash the measuring syringe with water and let it dry.
Poslije primjene veterinarsko-medicinskog proizvoda čvrsto zatvorite bočicu zatvaračem, mjernu štrcaljku operite s vodom i pustite da se osuši.
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Nakon primjene lijeka, zatvorite bočicu čepom, isperite mjernu štrcaljku toplom vodom i pustite da se osuši.
After administration of up to 10 times the recommended dose (20 mg/kg) to healthy dogs, dose- dependent adverse effects were noted (see section "Adverse Reactions").
Nakon primjene i do 10 puta preporučena doza (20 mg / kg) u zdravih pasa, nisu primijećeni štetni učinci ovisni o dozi (vidi „Nuspojave“)
After administration of up to 10 times the recommended dose (20 mg/kg) to healthy dogs, dose- dependent adverse effects were noted (see section 4.6).
Nakon primjene i do 10 puta veće doze od preporučene (20 mg / kg) u zdravih pasa, nisu primijećeni štetni učinci ovisni o dozi (vidjeti dio 4.6).
After administration of up to 5-fold of the recommended dose for 6 months, no adverse reactions were observed other than those mentioned in section "Adverse reactions".
Nakon primjene doze do 5 puta veće od preporučene tijekom 6 mjeseci, nisu bile opažene nuspojave osim onih navedenih u dijelu "Nuspojave".
After administration of up to 5-fold of the recommended dose for 6 months, no adverse reactions were observed other than those mentioned in section 4.6.
Nakon primjene doze do 5 puta veće od preporučene tijekom 6 mjeseci, nisu bile opažene nuspojave osim onih navedenih u dijelu 4.6.
After administration of VIZAMYL
Nakon primjene VIZAMYL-a
After administration of Xofigo
Nakon primjene lijeka Xofigo
After administration, change gloves prior to applying occlusive dressings to injected lesions.
Nakon primjene, promijenite rukavice prije nanošenja okluzivnog zavoja na lezije u koje je injiciran lijek.
After administration, fluoxetine readily appeared in plasma with mean Tmax values ranging from 1.25 to 1.75 hours on day 1 and from 2.5 to 2.75 hours on day 21.
Nakon primjene, fluoksetin se pokazivao u plazmi s vrijednostima Tmax od 1,25 do 1,75 sati na dan 1 i od 2,5 do 2,75 sati na dan 21.
After administration, occasionally sneezing, coughing, mild and transient discharge from the eyes or nose, may occur.
Nakon primjene p može doći do povremenog kihanja, kašljanja, blagi i prolazni iscjedka iz nosa i očiju.
After administration: Throw away any remaining solution as it should not be used beyond 20 minutes.
Nakon primjene: Svu preostalu otopinu treba baciti jer se ne smije primijeniti nakon što protekne 20 minuta.
After adminstration of Lymphoseek, you should?
Što morate učiniti nakon primjene lijeka Lymphoseek?
After an acute coronary syndrome patients on treatment with Xarelto and ASA or Xarelto and ASA plus clopidogrel/ticlopidine should only receive concomitant treatment with NSAIDs if the benefit outweighs the bleeding risk.
Nakon akutnog koronarnog sindroma, bolesnici koji se liječe lijekom Xarelto i ASA ili lijekom Xarelto i ASA uz dodatak klopidogrela/tiklopidina smiju biti istodobno liječeni nestereoidnim protuupalnim lijekovima samo ako je korist veća od rizika od krvarenja.
After an average of 36 months of treatment, the mean annualised rate of change in eGFRCKD-EPI was -0.81 mL/min/1.73 m2 (95% CI: -2.00, 0.37).
Nakon prosječnog razdoblja od 36 mjeseci liječenja, srednja godišnja stopa promjene u eGFRCKD-EPI iznosila je -0,81 mL/min/1,73 m2 (95 % CI: –2,00; 0,37).
After an increase in dose an additional test will be done after 2 weeks.
Nakon povećanja doze treba napraviti nove nalaze nakon 2 tjedna.
After an initial increase in visual acuity (following monthly dosing), on average, patients’ visual acuity declined with quarterly dosing, returning to baseline at Month 12 and this effect was maintained in most ranibizumab-treated patients (82%) at Month 24.
Nakon početnog poboljšanja vidne oštrine (nakon doziranja jednom mjesečno), ona se, u prosjeku, smanjila u bolesnika koji su Lucentis nastavili primati jednom svaka tri mjeseca te se u 12. mjesecu vratila na početnu razinu, a taj se učinak zadržao kod većine bolesnika liječenih ranibizumabom (82%) u 24. mjesecu.
After an oral dose of metformin, tmax is reached in 2.5 h.
Nakon peroralne doze metformina, tmax se postiže u 2,5 h.
After an oral dose of metformin, tmax is reached in 2.5 h.
Nakon peroralne doze metformina, tmax se postiže za 2,5 h.
After an oral dose of metformin, tmax is reached in 2.5 h.
Nakon peroralne primjene metformin postiže tmax za 2,5 h.
After an oral dose of metformin, tmax is reached in 2.5 h.
Nakon primjene peroralne doze metformina, tmax se postiže za 2,5 h.
After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.
Neapsorbirana frakcija u stolici bila je nakon peroralne doze 20-30%.
After an oral glucose load, this DPP4 inhibition resulted in a 2-to 3-fold increase in circulating levels of active incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness, which resulted in higher insulin and C-peptide concentrations.
Nakon oralnog opterećenja glukozom ta je inhibicija DPP-4 uzrokovala dvostruki do trostruki porast cirkulirajućih razina aktivnih inkretinskih hormona, uključujući glukagonu sličan peptid 1 (engl. glucagon-like peptide 1, GLP-1) te inzulinotropni polipeptid ovisan o glukozi (engl. glucose-dependent insulinotropic polypeptide, GIP), sniženje koncentracija glukagona te povećanje o glukozi ovisnog odgovora beta stanica, zbog čega su se povećale koncentracije inzulina i C-peptida.
After an oral single-dose (200 mg), AUC was 233 % higher in subjects with mild to moderate hepatic cirrhosis (Child-Pugh A and B) compared with subjects with normal hepatic function.
Nakon primjene jedne peroralne doze (200 mg) AUC je bio 233% veći u ispitanika s blagom do umjereno teškom cirozom jetre (Child-Pugh stadij A i B) u usporedbi s ispitanicima s normalnom jetrenom funkcijom.
After an oral single-dose (200 mg), AUC was 233% higher in subjects with mild to moderate hepatic cirrhosis (Child-Pugh A and B) compared with subjects with normal hepatic function.
Nakon primjene jedne peroralne doze (200 mg) AUC je bio 233% veći u ispitanika s blagom do umjereno teškom cirozom jetre (Child-Pugh stadij A i B) u usporedbi s ispitanicima s normalnom jetrenom funkcijom.
After any dose or schedule adjustment the haemoglobin should be monitored every one or two weeks.
Nakon svakog prilagođavanja doze ili rasporeda uzimanja, hemoglobin se mora odrediti svaki tjedan ili svaka 2 tjedna.
After application do not stroke or groom animals until the application site is dry.
Poslije nakapavanja ne smije se dirati životinje dok se mjesto aplikacije ne osuši.
after around 12 and 24 weeks (end of maintenance phase), and thereafter when clinically indicated.
nakon približno 12 i 24 tjedna (kraj faze održavanja) i nakon toga kada je klinički indicirano.
after around 3 weeks,
nakon približno 3 tjedna,
after around 6 weeks (end of acute phase),
nakon približno 6 tjedana (kraj akutne faze),
After assessment of the symptoms, the dose of Invega can be adjusted to between 3 and 12 mg once a day in adults with schizophrenia and to between 6 and
Nakon procjene simptoma, doza lijeka Invega može se prilagoditi između 3 i 12 mg jednom dnevno u odraslih koji boluju od shizofrenije i između 6 i 12 mg jednom dnevno u
After at least one week, the dose is increased to 1.2 mg.
Nakon najmanje tjedan dana doza se povećava na 1,2 mg.
After baseline and placebo adjustment, the maximum mean QTcF change was 3.2 ms (1-sided 95% Upper CI: 5.6 ms) for the 500/200 mg dose and 8.3 ms (1-sided 95% Upper CI: 10.8 ms) for the supra-therapeutic 750/200 mg dose.
Uz korekciju za bazalne vrijednosti i vrijednosti nakon izlaganja placebu, maksimalna prosječna QTcF promjena iznosila je 3,2 ms (gornja granica 95% CI:5,6 ms) za dozu od 500/200 mg, te 8,3 ms (gornja granica 95% CI: 10,8 ms) za supraterapijsku dozu od 750/200 mg.
After being given its actions last for 12 weeks against fleas and 8 to 12 weeks against ticks.
Nakon što se primijeni, VMP Bravecto djeluje 12 tjedana protiv buha i 8 do 12 tjedana protiv krpelja.
After being given, its actions last for 5 weeks against fleas and one month against ticks.
Nakon primjene, djelovanje protiv buha je 5 tjedana i jedan mjesec protiv krpelja.
After being given, its actions last for 5 weeks against fleas and one month against ticks.
Nakon što se primjeni u pasa, VMP djeluje 5 tjedana protiv buha i jedan mjesec protiv krpelja.
After being properly trained and with the agreement of their doctor, patients may inject themselves.
Nakon što prođu odgovarajuću obuku i uz suglasnog svog liječnika, bolesnici se mogu samoinjicirati.
After being treated with Angiox for a cardiac event, you should stay in the hospital for at least 24 hours and you should be monitored for any symptoms or signs similar to the ones that remind you of your cardiac event and resulted in your hospitalisation.
Nakon liječenja lijekom Angiox zbog srčanog događaja, morate ostati u bolnici tijekom najmanje 24 sata i mora Vas se nadzirati na bilo koje simptome ili znakove slične onima koji Vas podsjećaju na Vaš srčani događaj zbog čega ste i primljeni u bolnicu.
After cap is removed, if tamper evident snap collar is loose, remove before using the product.
Nakon skidanja poklopca, ukoliko je zaštitni obruč za evidenciju otvaranja klimav, uklonite ga prije primjene lijeka
After cap is removed, if the tamper evident snap collar is loose, remove before using the medicinal product.
Nakon skidanja poklopca, ukoliko je zaštitni obruč za evidenciju otvaranja klimav, uklonite ga prije primjene lijeka.
After cap is removed, if the tamper evident snap collar is loose, remove before using the product.
Nakon skidanja poklopca, ukoliko je zaštitni obruč za evidenciju otvaranja klimav, uklonite ga prije primjene lijeka.
After cartridge insertion
Nakon umetanja uloška
After chickenpox, the varicella-zoster virus stays in the body, in the nervous system, in a ‘dormant’ (inactive) state.
Nakon što osoba preboli vodene kozice, virus varicella-zoster ostaje u tijelu, u živčanom sustavu, u stanju „mirovanja” (neaktivnom stanju).
After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mm Hg).
Nakon kronične primjene doze od 80 mg tri puta na dan u bolesnika s plućnom arterijskom hipertenzijom opaženi su slabiji učinci na sniženje krvnog tlaka (sniženje i sistoličkog i dijastoličkog tlaka za 2 mmHg).
After chronic dosing of 80 mg three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mm Hg and 9.1 mm Hg respectively.
Nakon kronične primjene doze od 80 mg tri puta na dan u bolesnika sa sistemskom hipertenzijom, srednja vrijednost promjene u odnosu na početne vrijednosti činilo je sniženje sistoličkog i dijastoličkog krvnog tlaka za 9,4 mmHg, odnosno, 9,1 mmHg.
After chronic oral dosing of 80 mg three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mm Hg respectively.
Nakon kronične primjene peroralne doze od 80 mg tri puta na dan u bolesnika sa sistemskom hipertenzijom, srednja vrijednost promjene u odnosu na početne vrijednosti činilo je sniženje sistoličkog i dijastoličkog krvnog tlaka za 9,4 mmHg, odnosno 9,1 mmHg.
After cleaning
Nakon čišćenja
After cleaning, do not touch the stopper with your hands or allow it to touch any surface.
Nakon čišćenja, čep ili druge površine više nemojte dirati rukama.
After clinical reassessment dose may be adjusted within the range 150 mg to 300 mg every 2 weeks or 300 to 405 mg every 4 weeks. (Table 1)
Nakon ponovne kliničke procjene dozu se može prilagođavati unutar raspona od 150 mg do 300 mg svaka dva tjedna ili od 300 do 405 mg svaka četiri tjedna (Tablica 1).
After co- administration of spironolactone (2 mg/kg bw) and benazepril hydrochloride (0.25 mg/kg bw) the terminal plasma half-lives (t½) were 7 hours and 6 hours for canrenone and 7-α-thiomethyl- spironolactone respectively.
Nakon istovremene primjene spironolaktona (2 mg/kg tjelesne težine) i benazepril hidroklorida (0,25 mg/kg tjelesne težine), terminalni poluživoti u plazmi (t) iznosili su 7 odnosno 6 sati za kanrenon i 7-alfa-tiometil- spironolakton.
After co-administration of bosentan for 9.5 days, the plasma exposures to lopinavir and ritonavir decreased to a clinically non significant extent (by approximately 14% and 17%, respectively).
Nakon istodobne primjene bosentana kroz 9,5 dana, izloženost lopinaviru i ritonaviru u plazmi se smanjila u klinički neznačajnom opsegu (približno 14% odnosno 17%).